|
|
Volumn 32, Issue 7, 2014, Pages 626-632
|
|
Public biotech 2013-the numbers
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABIRATERONE ACETATE;
ADALIMUMAB;
AFLIBERCEPT;
AMYLIN;
BIOSIMILAR AGENT;
CANCER VACCINE;
CARFILZOMIB;
ECULIZUMAB;
FUMARIC ACID DIMETHYL ESTER;
INFLIXIMAB;
INSULIN GLARGINE;
LENALIDOMIDE;
NATALIZUMAB;
OXYBATE SODIUM;
RECOMBINANT GAMMA INTERFERON;
RITUXIMAB;
RUCAPARIB;
SOFOSBUVIR;
TELAPREVIR;
ANKYLOSING SPONDYLITIS;
ARTICLE;
BIOMEDICINE;
BIOTECHNOLOGY;
CANCER IMMUNOTHERAPY;
CANCER STEM CELL;
CELL METABOLISM;
CONSTIPATION;
DRUG COST;
DRUG INDUSTRY;
EPIGENETICS;
EXON SKIPPING;
FINANCIAL MANAGEMENT;
GENE THERAPY;
GENOMICS;
GEOGRAPHIC DISTRIBUTION;
HUMAN;
IRRITABLE COLON;
KIDNEY DISEASE;
MULTIPLE SCLEROSIS;
MYELOMA;
OVARY CANCER;
PECTOBACTERIUM CHRYSANTHEMI;
PRESCRIPTION;
PRIORITY JOURNAL;
PROSTATE CANCER;
RETINA MACULA AGE RELATED DEGENERATION;
RHEUMATOID ARTHRITIS;
RNA INTERFERENCE;
BIOTECHNOLOGY;
CAPITAL FINANCING;
PUBLIC SECTOR;
|
|
EID: 84903981129
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.2949 Document Type: Article |
|
Times cited : (15)
|
|
References (0)
|